Close

JPMorgan Resumes Idera Pharmaceuticals (IDRA) at Overweight

August 15, 2018 7:34 AM EDT Send to a Friend
JPMorgan resumes Anupam Rama initiates coverage on Idera Pharmaceuticals (NASDAQ: IDRA) with a Overweight rating and a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login